OCUPHIRE PHARMA DL-0001
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also dev… Read more
OCUPHIRE PHARMA DL-0001 (R3X1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, OCUPHIRE PHARMA DL-0001 (R3X1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
OCUPHIRE PHARMA DL-0001 - Net Assets Trend (None–None)
This chart illustrates how OCUPHIRE PHARMA DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OCUPHIRE PHARMA DL-0001 (None–None)
The table below shows the annual net assets of OCUPHIRE PHARMA DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to OCUPHIRE PHARMA DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
OCUPHIRE PHARMA DL-0001 Competitors by Market Cap
The table below lists competitors of OCUPHIRE PHARMA DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SmartCraft ASA
OL:SMCRT
|
$115.21 Million |
|
Zhejiang Wandekai Fluid Equipment Technology Co. Ltd. A
SHE:301309
|
$115.27 Million |
|
Chia Hsin Cement Corp
TW:1103
|
$115.31 Million |
|
Hanyang Digitech Co. Ltd
KQ:078350
|
$115.40 Million |
|
HEIMSTADEN AB PR.SHS O.N.
F:61B
|
$115.09 Million |
|
Berkeley Energia Ltd
AU:BKY
|
$115.09 Million |
|
Namyang Dairy
KO:003920
|
$115.08 Million |
|
Icon Offshore Bhd
KLSE:5255
|
$115.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OCUPHIRE PHARMA DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares OCUPHIRE PHARMA DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently OCUPHIRE PHARMA DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares OCUPHIRE PHARMA DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OCUPHIRE PHARMA DL-0001 (R3X1) | €- | N/A | N/A | $115.10 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |